{
    "pmcid": "11200683",
    "qa_pairs": {
        "How do bispecific VHH-Fc-VHH constructs enhance neutralization potency against SARS-CoV-2?": [
            "By combining two VHHs into a single molecule, enhancing resistance to antigenic escape",
            "By targeting only the conserved regions of the spike protein",
            "By increasing the immunogenicity of the antibody",
            "By reducing the size of the antibody to penetrate host cells"
        ],
        "What advantage do VHH single-domain antibodies have over traditional monoclonal antibodies in targeting SARS-CoV-2?": [
            "Smaller size, stability, and ease of production",
            "Higher immunogenicity and longer serum half-life",
            "Ability to target non-conserved regions of the virus",
            "Increased likelihood of antigenic escape"
        ],
        "What feature of the VHH platform allows for rapid adaptation to new SARS-CoV-2 variants?": [
            "The modular nature of the platform enabling rapid iteration and adaptation",
            "The use of animal-derived antibodies for increased diversity",
            "The focus on targeting only the original strain of the virus",
            "The reliance on traditional monoclonal antibody production methods"
        ],
        "What is the primary target for neutralizing antibodies in the development of VHH single-domain antibodies against SARS-CoV-2 variants?": [
            "The spike protein of SARS-CoV-2",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What method was used to map the epitopes of VHH antibodies on the SARS-CoV-2 spike protein?": [
            "Cryo-electron microscopy and alanine scanning mutagenesis",
            "X-ray crystallography and mass spectrometry",
            "NMR spectroscopy and computational modeling",
            "Western blotting and ELISA"
        ]
    }
}